Nature Clinical Practice Urology
Importance of Surgical Margins in the Management of Renal Cell Carcinoma CME

Disclosures

Release Date: May 13, 2008; Valid for credit through May 13, 2009
Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

Contents of This CME Activity
    To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

    Importance of Surgical Margins in the Management of Renal Cell Carcinoma
    John S. Lam, MD
    Jonathan Bergman, MD
    Alberto Breda, MD
    Peter G. Schulam, MD, PhD

Go to Test Questions

 
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.

 
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify historical parameters for referral to radical nephrectomy vs partial nephrectomy for renal cell carcinoma (RCC)
  2. Compare techniques of partial nephrectomy for RCC
  3. List management options for patients with RCC and positive surgical margins following partial nephrectomy
  4. Specify interventions that can reduce the risk for positive surgical margins following partial nephrectomy for RCC
Authors and Disclosures

John S. Lam, MD
Disclosure: John S. Lam, MD, has disclosed no relevant financial relationships.


Jonathan Bergman, MD
Disclosure: Jonathan Bergman, MD, has disclosed no relevant financial relationships.


Alberto Breda, MD
Disclosure: Alberto Breda, MD, has disclosed no relevant financial relationships.


Peter G. Schulam, MD, PhD
Disclosure: Peter G. Schulam, MD, PhD, has disclosed no relevant financial relationships.


Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc.


Nayanah Siva
Disclosure: Nayanah Siva has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.